Genentech have announced that its ongoing Phase III study of Avastin (bevacizumab) in patients with early-stage colon cancer will continue as planned.
Filed under: Uncategorized | Tagged: Avastin, bevacizumab, Genentech, kinase, phase iii, Roche, VEGF